Pediatric Hemorrhagic Moyamoya Disease: Clinical Course, Treatment, and Outcomes

Qingbao Guo1, Manli Xie2, Jingchun Wang1

  • 1Department of Neurosurgery, Xi'an No.9 Hospital Shaanxi, China.

Neurology
|January 29, 2026
PubMed
Abstract

Insights

Hemorrhagic moyamoya disease (MMD) in children is aggressive, often seen in older females. Anterior choroidal artery dilatation and higher admission disability scores predict worse outcomes and recurrence.

Area of Science:

  • Neuroscience
  • Pediatric Neurology
  • Vascular Neurology

Background:

  • Pediatric hemorrhagic moyamoya disease (MMD) presents a significant clinical challenge due to high morbidity.
  • Prognostic factors specifically related to hemorrhagic MMD in children are not well-defined.
  • Understanding these factors is crucial for improving patient outcomes and guiding treatment strategies.

Purpose of the Study:

  • To define the clinical course of pediatric hemorrhagic MMD.
  • To identify factors associated with hemorrhagic presentation and recurrence.
  • To evaluate the long-term outcomes in a large pediatric cohort with MMD.

Main Methods:

  • Retrospective cohort study of pediatric MMD patients (2003-2023).
  • Hemorrhagic MMD defined by acute intracranial hemorrhage (excluding trauma/aneurysm).
  • Data included Suzuki staging, PcomA/AChA dilatation, mRS scores, and recurrence events; analyzed using logistic regression and Cox models.

Main Results:

  • Hemorrhagic MMD cohort (117/1446 patients) was older and predominantly female.
  • Independent predictors for hemorrhagic MMD: AChA dilatation (aOR 5.95), PcomA dilatation (aOR 4.23), and admission mRS ≥2 (aOR 2.38).
  • AChA dilatation strongly predicted recurrent hematoma (HR 8.85); admission mRS ≥2 predicted all recurrence types (stroke, hematoma, infarction).

Conclusions:

  • Hemorrhagic MMD is an aggressive subtype with posterior collateral vulnerability, female predominance, and older age at presentation.
  • Admission mRS score ≥2 and AChA dilatation are critical indicators of adverse outcomes.
  • Focus on posterior circulation assessment is vital for outcome stratification and early intervention in pediatric MMD.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
946
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
646
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
369
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
939
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
485